Literature DB >> 23422689

Shikonin, a natural product from the root of Lithospermum erythrorhizon, is a cytotoxic DNA-binding agent.

Changmin Chen1, Kumaran Shanmugasundaram2, Alan C Rigby2, Andrew L Kung3.   

Abstract

To search for compounds that disrupt binding of the EWS-FLI1 fusion protein to its cognate targets, we developed a homogeneous high-throughput proximity assay and screened 5200 small molecule compounds. Many well-known DNA-binding chemotherapeutic agents, such as actinomycin D, cisplatin, doxorubicin, daunorubicin, and epirubicin scored in the assay and not surprising also disrupted the binding of other transcription factors. Unexpectedly, we found that Shikonin, a natural product from the root of Lithospermum erythrorhizon, similarly disrupted protein-DNA interactions. Mechanistic studies demonstrated that Shikonin displaces SYBR green from binding to the minor groove of DNA and is able to inhibit topoisomerase mediated DNA relaxation. In cells, Shikonin blocked the binding of EWS-FLI1 to the NR0B1 promoter, and attenuated gene expression. Shikonin rapidly induced G2/M arrest and apoptosis in Ewing sarcoma cells. These results demonstrate that contrary to other purported mechanisms of action, Shikonin is a DNA-binding cytotoxic agent.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23422689     DOI: 10.1016/j.ejps.2013.02.003

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  12 in total

Review 1.  Targeting Cancer Metabolism and Current Anti-Cancer Drugs.

Authors:  Witchuda Sukjoi; Jarunya Ngamkham; Paul V Attwood; Sarawut Jitrapakdee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  One-pot synthesis of 1,4-dihydroxy-2-((E)-1-hydroxy-4-phenylbut-3-enyl)anthracene-9,10-diones as novel shikonin analogs and evaluation of their antiproliferative activities.

Authors:  Li-Ming Zhao; Feng-Xia Cao; Hai-Shan Jin; Jie-Huan Zhang; Jeffrey Szwaya; Guangdi Wang
Journal:  Bioorg Med Chem Lett       Date:  2016-04-06       Impact factor: 2.823

3.  Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.

Authors:  Yitian Dai; Yuping Liu; Jingyi Li; Mingming Jin; Hao Yang; Gang Huang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 4.  Advances in the Treatment of Pediatric Bone Sarcomas.

Authors:  Patrick J Grohar; Katherine A Janeway; Luke D Mase; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 5.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

6.  Shikonin Induces Apoptosis, Necrosis, and Premature Senescence of Human A549 Lung Cancer Cells through Upregulation of p53 Expression.

Authors:  Yueh-Chiao Yeh; Tsun-Jui Liu; Hui-Chin Lai
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-09       Impact factor: 2.629

7.  The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis.

Authors:  Zeze Fu; Biyong Deng; Yuxin Liao; Liancheng Shan; Fei Yin; Zhuoying Wang; Hui Zeng; Dongqing Zuo; Yingqi Hua; Zhengdong Cai
Journal:  BMC Cancer       Date:  2013-12-06       Impact factor: 4.430

8.  Shikonin causes apoptosis by disrupting intracellular calcium homeostasis and mitochondrial function in human hepatoma cells.

Authors:  Hui Wang; Zheng Liu; Xiangchen Li; Ruijie Zhao; Yabin Pu; Handong Wu; Weijun Guan
Journal:  Exp Ther Med       Date:  2017-12-05       Impact factor: 2.447

9.  Differential disruption of EWS-FLI1 binding by DNA-binding agents.

Authors:  Changmin Chen; Diane R Wonsey; Madeleine E Lemieux; Andrew L Kung
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

10.  Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.

Authors:  Kelli L Goss; Stacia L Koppenhafer; Kathryn M Harmoney; William W Terry; David J Gordon
Journal:  Oncotarget       Date:  2017-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.